EUCTR2016-004728-48-Outside-EU/EEA进行中（未招募）1 期
A Study to Evaluate the Comparative Bioavailability of the Investigational Oral Pediatric Minitablet Formulation of MK-1439 Compared to the Adult Formulation of MK-1439 in Healthy Adult Subjects - Pediatric Formulation Study
Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc.0 个研究点目标入组 24 人开始时间: 2016年11月23日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Non-tobacco using males and non-pregnant females, 18-55 years of age, inclusive.
- •2. A body mass index (BMI) of 18-30 kg/m² inclusive as calculated according to Novum Standard Operating Procedures.
- •3. Alkaline phosphatase, alanine transaminase (ALT/SGPT), aspartate transaminase (AST/SGOT), and bilirubin (total and direct) are below the upper limit of normal based on the clinically acceptable normal range; obtained from the clinical laboratory tests performed at screening.
- •4. If female and of childbearing potential, prepared to abstain from sexual intercourse, or have used and agree to continue to use a reliable method of contraception (e.g., hormonal contraceptives, condom with spermicide, IUD) for at least 30 days before initial dosing and throughout the duration of the study.
- •5. Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.
- •6. Able to consume the entire contents of a 6 oz. container of lowfat vanilla or french vanilla yogurt (e.g., Stonyfield Organic™ Smooth & Creamy lowfat french vanilla yogurt) within 10 minutes, at screening.
- •7. Signed and dated written informed consent form for the trial, which meets all criteria of current ICH, FDA and state regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Females who are pregnant, lactating or likely to become pregnant during the study.
- •2. History of allergy or sensitivity to MK-1439 or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of study.
- •3. Lactose intolerant.
- •4. Significant history or current evidence of chronic infectious disease, system disorders, organ dysfunction, especially cardiovascular disorders (angina, heart failure, irregular heartbeats, heart attack, hypertension, hypotension), stroke, renal or hepatic disorder, diabetes or bleeding disorders.
- •5. Clinically significant history or presence of gastrointestinal disease or malabsorption within the last year, as determined by the Investigator.
- •6. Presence of a medical condition requiring regular treatment with prescription drugs (except hormonal contraceptives).
- •7. History of psychiatric disorders occurring within the last two years that required the subject to be hospitalized or treated with medication.
- •8. Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes (e.g., CYP3A4) within 30 days before initial dosing.
- •9. Receipt of any drug as part of a research study within 30 days before initial dosing.
- •10. Drug or alcohol addiction requiring treatment in the past 12 months.
- •11. History of excessive alcohol consumption (on average more than 14 units of alcohol/week) during the past 12 months.
- •12. Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days before initial dosing.
- •13. Positive test for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
- •14. Positive test results for drugs of abuse at screening.
- •15. If female, has a positive serum pregnancy test at screening.
- •16. Use of tobacco products, or other nicotine containing products such as patches or gum within 90 days before initial dosing.
- •17. Difficulty fasting, eating yogurt, or eating the standard meals that will be provided during the study.
研究者
相似试验
已完成
不适用
A Study to Evaluate the Comparative Bioavailability of One Tablet of 480 mg MK-8228 and Two Tablets of 240 mg MK-8228 Under Fasted Conditions in Healthy SubjectsCMV infectionvirus infection10047438NL-OMON40940Merck Sharp & Dohme (MSD)14
已完成
不适用
A Study to Evaluate the Comparative Bioavailability of Formulation Batches of MK-3682A Fixed-Dose Combination Tablet (MK-3682/MK-5172/MK-8742, 225 mg/50 mg/25 mg) in Healthy Adult SubjectsNL-OMON42602Merck Sharp & Dohme (MSD)16
已完成
Unknown
Absorption and availability of NCT023 extract in blood in healthy volunteersCTRI/2023/10/058565isarga Biotech Pvt. Ltd.14
已完成
不适用
A Study to Evaluate the Relative Bioavailability and Effect of Food on Two Formulations of the MK-3682A Fixed-Dose Combination Tablets (MK-3682/MK-5172/MK-8742, 300 mg/ 100 mg/50 mg) in Healthy Adult Subjects.HCVHepatitis C virus10047438NL-OMON41736Merck Sharp & Dohme (MSD)22
已完成
不适用
A study to evaluate the relative bioavailability and effect of food on two 450mg MK-3682 Fixed-Dose Combination Formulations (MK-3682 /MK-5172 /MK-8408)10047438Hepatitis CNL-OMON41967Merck Sharp & Dohme (MSD)24